Total Bilirubin

Your body destroys millions of red blood cells every day as they wear out, and bilirubin is what is left over. It is a yellow pigment, the same molecule that gives bruises their greenish-yellow tinge as they heal. Most of the time, your liver grabs this pigment from the bloodstream, converts it into a water-soluble form, and dumps it into bile for elimination. When that system works well, bilirubin stays low. When something disrupts any step, from excess red blood cell destruction to a sluggish liver to a blocked bile duct, bilirubin backs up into the blood.

But bilirubin is not simply a waste product waiting to be cleared. Research over the past two decades has revealed that mildly elevated bilirubin within the normal range acts as an antioxidant and anti-inflammatory molecule, and people whose bilirubin naturally runs a bit higher appear to be protected against heart disease, certain cancers, kidney disease, and early death. This dual identity, a marker of liver trouble when it is very high yet a shield against chronic disease when it is modestly elevated, makes bilirubin one of the more interesting numbers on a standard blood panel.

Total Bilirubin (Unconjugated + Conjugated)

Total bilirubin is actually the sum of two forms. The first is unconjugated (indirect) bilirubin, which is the raw pigment released when red blood cells break down. It is not water-soluble, so it travels through the blood attached to a carrier protein called albumin. The second is conjugated (direct) bilirubin, the processed version that the liver has chemically modified by attaching a sugar molecule (glucuronic acid) so it can dissolve in bile and be excreted. Your total bilirubin reading combines both. If it is elevated, the next step is always to check which form is driving the increase, because the two forms point to completely different causes.

Unconjugated bilirubin rises when red blood cells are being destroyed faster than normal (a process called hemolysis) or when the liver's processing enzyme is sluggish, as happens in Gilbert syndrome, a harmless genetic trait affecting 3% to 7% of the population. Conjugated bilirubin rises when the liver itself is damaged (hepatitis, cirrhosis, drug injury) or when bile flow is physically blocked (gallstones, tumors). This distinction is so fundamental that an elevated total bilirubin without fractionation tells you very little on its own.

Heart Disease Risk

The relationship between bilirubin and cardiovascular disease is one of the most replicated findings in the field. A meta-analysis pooling 12 population-based studies with 9,378 cardiovascular events found that for every standard-deviation increase in total bilirubin, the risk of cardiovascular disease dropped by 7%, and the risk of stroke dropped by 7% as well. These associations held after adjusting for standard cardiovascular risk factors like blood pressure, cholesterol, and smoking.

A separate systematic review of 12 prospective studies covering 368,567 participants identified a U-shaped dose-response relationship between bilirubin and cardiovascular risk. The lowest cardiovascular risk appeared at bilirubin levels of roughly 1.0 to 1.2 mg/dL (17 to 20 micromoles per liter, a unit for measuring small concentrations in blood). Both very low bilirubin (below this range) and very high bilirubin (above it) were associated with increased risk, though the very highest bilirubin levels likely reflect underlying liver disease rather than a failure of antioxidant protection.

A study of 331,002 participants in the UK Biobank used a genetic technique called Mendelian randomization (which tests whether an association is likely causal, not just a correlation) and found that genetically higher bilirubin was linked to about an 8% lower odds of cardiovascular disease, a 10% lower odds of coronary heart disease, and a 9% lower odds of hypertensive disease. This suggests bilirubin's cardiovascular protection is at least partly a direct biological effect, not just a marker of something else.

What this means for you: if your bilirubin consistently runs at the low end of the normal range (below 0.4 mg/dL), this body of evidence suggests you may be missing out on a natural cardiovascular buffer. That does not mean you should try to raise it artificially, but it does mean a low bilirubin adds context to your broader cardiovascular risk profile, especially if other markers like LDL cholesterol or inflammatory markers are borderline.

Mortality Risk

Both very low and very high bilirubin levels are associated with an increased risk of dying. A study of 44,508 participants followed for an average of 12.5 years found a J-shaped relationship: bilirubin levels at either extreme predicted higher mortality from multiple causes. Among 4,303 older adults in a U.S. cohort, those with bilirubin between 0.1 and 0.4 mg/dL had a 36% higher risk of death compared to those with levels between 0.5 and 0.7 mg/dL, even after adjusting for age, sex, smoking, and chronic conditions.

In a study of 12,000 treated hypertensive patients followed for 35 years, bilirubin showed a significant negative association with both cardiovascular and all-cause mortality. Adding bilirubin to conventional risk factors improved the ability to correctly classify who would die from cardiovascular disease by 8% to 26%, depending on the time horizon. The consistent signal across these large, long-term studies is that bilirubin in the range of roughly 0.5 to 1.0 mg/dL appears to be associated with the best survival outcomes.

Cancer Associations

Bilirubin's antioxidant properties appear to extend to cancer protection, though the picture is more complex than with heart disease. In a Japanese study of 29,080 subjects, lower baseline bilirubin was associated with higher cancer incidence, and in a case-cohort study of 3,584 cancer cases with 15.8 years of follow-up, the highest bilirubin group had about 14% lower risk of all cancers after excluding liver cancer. A meta-analysis found that higher bilirubin was associated with about a 31% lower risk of lung cancer.

The relationship with gastrointestinal cancers is more nuanced. In 440,948 UK Biobank participants, higher bilirubin was linked to a 28% lower risk of esophageal cancer but roughly double the risk of liver cancer and a 67% higher risk of bile duct cancer. This makes biological sense: liver and bile duct cancers cause bilirubin to rise by obstructing bile flow, so elevated bilirubin in these cases is a consequence of the cancer, not a protective factor. A Korean study of 78,467 adults found higher bilirubin associated with 26% lower risk of colorectal cancer, with the lowest risk at approximately 0.8 mg/dL.

Kidney Disease

A systematic review including 11 studies with 41,188 participants found that people with the highest bilirubin levels had a 36% lower risk of chronic kidney disease compared to those with the lowest levels. For every 0.2 mg/dL increase in bilirubin, kidney disease risk dropped by about 11%. The relationship followed a consistent negative linear pattern, meaning that higher bilirubin was continuously associated with better kidney protection across the range studied.

Diabetes

The connection between bilirubin and type 2 diabetes is less straightforward. The PREVEND study of 3,381 participants used Mendelian randomization to estimate a 42% causal risk reduction for type 2 diabetes per standard-deviation increase in bilirubin. However, the much larger UK Biobank Mendelian randomization analysis (331,002 participants) found no statistically significant causal link between genetically determined bilirubin and diabetes. And a Chinese cohort of 12,530 diabetes-free adults found a U-shaped relationship for total bilirubin, where both very low and very high levels were associated with higher diabetes risk. The evidence here is mixed, and bilirubin should not be treated as a reliable diabetes risk indicator on its own.

Reference Ranges

Men typically have higher bilirubin than women (average 0.72 mg/dL vs. 0.52 mg/dL in U.S. data), and ethnicity matters too: non-Hispanic Black adults average about 0.55 mg/dL compared to 0.63 mg/dL for non-Hispanic white adults. Genetic variation in the UGT1A1 enzyme, the liver enzyme responsible for processing bilirubin, is a major determinant of your baseline level. Always compare your results within the same lab over time, since different labs use slightly different assays and cutpoints.

These tiers are drawn from published research, including the NHANES III population study and prospective outcome data. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. A Finnish validation study placed the upper reference limit at 1.64 mg/dL for men and 1.46 mg/dL for women using the 97.5th percentile.

Gilbert Syndrome: The Most Common Cause of Mild Elevation

If your bilirubin runs between 1.0 and 3.0 mg/dL and the rest of your liver enzymes are normal, the most likely explanation is Gilbert syndrome, a genetic variant that reduces the activity of the bilirubin-processing enzyme UGT1A1 to about 30% of normal. This is not a disease. It requires no treatment, causes no liver damage, and about 30% of people who have it never show symptoms. The main practical consequence is that your bilirubin will spike during fasting, illness, or physical stress, which can trigger unnecessary worry if you or your clinician are not aware of the condition.

In fact, Gilbert syndrome may actually be protective. The modestly elevated bilirubin associated with this condition falls squarely in the range linked to lower cardiovascular disease risk, lower cancer incidence, and better survival in large population studies. If you have been told you have Gilbert syndrome, you can stop worrying about it and start thinking of it as a minor metabolic advantage.

When Results Can Be Misleading

Bilirubin has one of the highest short-term variabilities among liver markers, with a within-subject coefficient of variation of 23.4% over roughly 17 days. That means your result can swing by nearly a quarter just from normal biological fluctuation, which is substantially higher than ALT (13.9%) or alkaline phosphatase (6.7%). In practical terms, 38% of adults with an initially elevated bilirubin had a normal result when retested about two and a half weeks later.

Fasting is the single biggest confounder. Skipping meals or fasting for more than 12 hours can increase unconjugated bilirubin by two to three times its baseline, especially in people with Gilbert syndrome. This effect reverses rapidly with eating, particularly with glucose-containing foods. If your blood was drawn after an overnight fast (as most lab work requires), your bilirubin may read higher than your true resting level.

Diurnal variation also matters. Bilirubin peaks at different times depending on your sleep schedule, with an intra-individual coefficient of variation ranging from 12.8% to 42.5% across the day. For the most consistent results, draw blood in the morning after a normal night of sleep. Acute illness and major surgery can spike bilirubin independently of any liver problem, as can significant hemolysis from blood transfusions. Statins modestly increase bilirubin by 10% to 15% through effects on liver transport proteins, not through liver damage. This is a testing artifact, not a sign of statin toxicity.

Tracking Your Trend

Given bilirubin's 23.4% short-term variability, a single reading is a rough snapshot at best. The real value comes from watching how your level moves over time. A gradually rising trend over months or years could signal developing liver disease, increasing red blood cell destruction, or a bile flow problem, all long before symptoms appear. A consistently low level, especially below 0.4 mg/dL, may warrant a closer look at your cardiovascular risk profile given the strong associations with heart disease and mortality.

Get a baseline reading, and if your value falls outside the optimal range or you are making lifestyle changes that could affect liver health (changing medications, adjusting alcohol intake, starting an exercise program), retest in 3 to 6 months. After that, annual monitoring is reasonable for most people. If an initial result comes back elevated, always retest before pursuing extensive workup, since more than a third of mildly elevated results normalize on their own. When retesting, try to match the conditions: same lab, same time of day, similar fasting duration.